Results 161 to 170 of about 1,177,085 (276)

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. [PDF]

Eye (Lond)
Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, Lawrence D, Holz FG.   +6 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration. [PDF]

Clin Ophthalmol
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH.   +11 more
europepmc   +1 more source

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. [PDF]

Sci Rep, 2023
Matsumoto H, Hoshino J, Nakamura K, Akiyama H.   +3 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration. [PDF]

BMC Ophthalmol
Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK.   +4 more
europepmc   +1 more source

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. [PDF]

Sci Rep, 2022
Kim JH, Kim JW, Kim CG.
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Iori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH   +11 more
doaj  

Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol. [PDF]

Ophthalmol Sci
Saucedo L, Pfister IB, Schild C, Garweg JG.   +3 more
europepmc   +1 more source